Psychotropic drug safety in pregnancy
Results of recent studies on antipsychotic use during pregnancy have shown that atypical antipsychotic drugs could dysregulate the metabolic function of women before rather than during pregnancy, potentially leading to long-term and unfavourable maternal and neonatal outcomes. This study will investigate whether pre-conception exposure to second generation antipsychotic agents is associated with adverse maternal and neonatal outcomes by increasing the relative risk of gestational diabetes.